Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 138000
Corporate User License Price USD 6000
Corporate User License Price INR 414000
Site License Price USD 4000
Site License Price INR 276000
Request a Quote

Report Title

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline Review, H2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline Review, H2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline Review, H2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline Review, H2 2017



Executive Summary

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline Review, H2 2017, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 8, 47 and 26 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 5 molecules, respectively.

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 5

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Overview 6

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Therapeutics Development 7

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Therapeutics Assessment 22

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Companies Involved in Therapeutics Development 32

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Drug Profiles 56

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Dormant Projects 233

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Discontinued Products 237

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Product Development Milestones 238

Appendix 252

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Abivax SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Adimab LLC, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Akshaya Bio Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by AnGes MG Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by ANP Technologies Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Arno Therapeutics Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Atreca Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by BioCryst Pharmaceuticals Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by BioFactura Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Cadila Healthcare Ltd, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Celgene Corp, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Cocrystal Pharma Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Eisai Co Ltd, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Emergent BioSolutions Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Enyo Pharma SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Etubics Corp, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Fab'entech SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Fujifilm Holdings Corporation, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Gilead Sciences Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by GlaxoSmithKline Plc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Globavir Biosciences Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Hemispherx Biopharma Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Humabs BioMed SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Immune Response BioPharma Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Immunovaccine Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Integrated BioTherapeutics Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Johnson & Johnson, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Kineta Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Medicago Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Merck & Co Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Microbiotix Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Micropharm Ltd, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by NanoViricides Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Navigen Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Novavax Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Peregrine Pharmaceuticals Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Phelix Therapeutics LLC, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by PlantForm Corp, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Profectus BioSciences Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by RedHill Biopharma Ltd, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Rodos BioTarget GmbH, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by SignPath Pharma Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Sirnaomics Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Soligenix Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Taiga Biotechnologies Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Tamir Biotechnology Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Theravectys SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by Vaccibody AS, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Pipeline by XBiotech Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Dormant Projects, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Dormant Projects, H2 2017 (Contd..1), H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Dormant Projects, H2 2017 (Contd..2), H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Dormant Projects, H2 2017 (Contd..3), H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever)-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Abivax SA

Adimab LLC

Akshaya Bio Inc

AnGes MG Inc

ANP Technologies Inc

Arno Therapeutics Inc

Atreca Inc

BioCryst Pharmaceuticals Inc

BioFactura Inc

Cadila Healthcare Ltd

Celgene Corp

Cocrystal Pharma Inc

Eisai Co Ltd

Emergent BioSolutions Inc

Enyo Pharma SA

Etubics Corp

Fab'entech SA

Fujifilm Holdings Corporation

Gilead Sciences Inc

GlaxoSmithKline Plc

Globavir Biosciences Inc

Hemispherx Biopharma Inc

Humabs BioMed SA

Immune Response BioPharma Inc

Immunovaccine Inc

Inovio Pharmaceuticals Inc

Integrated BioTherapeutics Inc

Johnson & Johnson

Kineta Inc

Medicago Inc

Merck & Co Inc

Microbiotix Inc

Micropharm Ltd

NanoViricides Inc

Navigen Inc

Novavax Inc

Peregrine Pharmaceuticals Inc

Phelix Therapeutics LLC

PlantForm Corp

Profectus BioSciences Inc

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Rodos BioTarget GmbH

SignPath Pharma Inc

Sirnaomics Inc

Soligenix Inc

Taiga Biotechnologies Inc

Tamir Biotechnology Inc

Theravectys SA

Vaccibody AS

XBiotech Inc

Ebolavirus Infections (Ebola Hemorrhagic Fever) Therapeutic Products under Development, Key Players in Ebolavirus Infections (Ebola Hemorrhagic Fever) Therapeutics, Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline Overview, Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline, Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person